 Spectrum --
August 2008
 Introduction:
Mounting evidence that a growing number of women are
choosing to delay childbirth into their mid-to-late thirties highlights a
significant opportunity for new and efficacious infertility treatments. Despite
the increasing level of need, the treatment of infertility has not changed
significantly over the past several decades because drug developers have been
put off by the relatively small market, reimbursement concerns, and the
efficacy of existing treatment. However, there is room in this market for an
agent that can address the infertility issues of the moderately high percentage
of women who have failed existing treatments.
Get the Answers You Need to Shape Your Strategy:
 It has long been established that fertility in women drops
after age 35; however, an increasing number of women are waiting until this age
to have children. What are the primary causes of infertility? What are the
age ranges most highly affected by infertility, according to surveyed
specialists?
The newest agent for the treatment of infertility was approved
in 2007; however, the most commonly prescribed agent is several decades old. What
are the prescribing patterns of specialists for the various causes of
infertility? What are the overall success rates of infertility treatments? What
reimbursement policies are in place for infertility treatments?
A significant percentage of women who undergo fertility
treatments still fail to conceive. What emerging agents are being developed
for infertility? What benefits do these agents offer over existing agents? What
is the likelihood that these agents will establish a position in the
infertility market?
Scope:
Overview of infertility: normal menstrual cycle and
fertility, causes of infertility.
Currently approved treatments for infertility:
clomiphene citrate, follicle-stimulating hormones, human menopausal hormones,
Schering-Plough’s Ganirelix, Merck Serono’s Ovidrel.
Medical practice: U.S. specialists surveyed to
determine current prescribing patterns for various types of infertility.
Emerging treatments: a review of the infertility
pipeline, including the lead agent, Schering-Plough’s corifollitropin alfa.
Outlook for the infertility market: current market
drivers and constraints, adoption of emerging agents.
Women’s Health Series: In 2007, the market for
women’s reproductive health exceeded $23 billion worldwide. In the Women’s
Health Series, we examine three specific markets, focusing on areas of
unmet need and the best marketing strategies to ensure adoption of a new agent.
We will provide insight from a variety of thought leaders on the current state
of disease treatment and their opinions on the most promising agents currently
in the pipeline.
|
